Boston (PRWEB) October 29, 2007 -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, announced that data from a 12-month study (www.daytrana.com) of DAYTRANATM (methylphenidate transdermal system), the Attention Deficit Hyperactivity Disorder (ADHD) patch, demonstrated that DAYTRANA provided significant ADHD tolerability and symptom control improvement in children aged 6 to 12 years. The study data was presented today at a major scientific and educational meeting of child and adolescent psychiatrists held in Boston, and is consistent with data previously presented.
?In our study, children with ADHD experienced effective ADHD symptom control improvement when using DAYTRANA for 12 months, improving their ability to maintain focus and concentration in and outside of the classroom,? reported investigator Frank A. López, M.D., neurodevelopmental pediatrician at the Children?s Developmental Center, Winter Park, Fla. ?Importantly, this year-long study showed that DAYTRANA maintained a favorable safety profile throughout the study period, with adverse events consistent with previous DAYTRANA studies.?
Shire?s DAYTRANA is the first and only patch medication approved by the U.S. Food and Drug Administration (FDA) to treat the symptoms of ADHD in children aged 6 to 12 years. The study results demonstrate that adverse events associated with DAYTRANA were similar to other methylphenidate products. The most common adverse events reported in this study were decreased appetite, headache, upper respiratory tract infection, cough, fever, and decreased weight. When worn for the recommended nine hours, efficacy has been demonstrated from the first time point measured (two hours) through the 12-hour time point. Because DAYTRANA is a patch, physicians may recommend that patients shorten the wear time if shorter duration of effect is desired or to help manage the potential for late-day side effects, such as lack of appetite or difficulty sleeping.
López added, ?DAYTRANA?s novel patch delivery system offers physicians and parents of children with ADHD a convenient, non-oral option to individualize ADHD treatment to meet their children?s changing schedules.?
While this study evaluated the safety and effectiveness of DAYTRANA for up to 12 months, DAYTRANA has not been studied versus placebo for longer than 7 weeks. Physicians, who prescribe DAYTRANA for long-term use, should periodically re-evaluate patients to assess the usefulness of DAYTRANA for the individual patient.
The study was supported by funding from Shire.
About ADHD:
Approximately 7.8 percent of all school-age children, or about 4.4 million U.S. children aged 4 to 17 years, have been diagnosed with ADHD at some point in their lives, according to the U.S. Centers for Disease Control and Prevention (CDC). ADHD is one of the most common psychiatric disorders in children and adolescents. ADHD is a neurobiological psychiatric disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that is more frequent and severe than is typically observed in individuals at a comparable level of development. To be properly diagnosed with ADHD, a child needs to demonstrate at least six of nine symptoms of inattention; and/or at least six of nine symptoms of hyperactivity/impulsivity; the onset of which appears before age 7 years; that some impairment from the symptoms is present in two or more settings (e.g., at school and home); that the symptoms continue for at least six months; and that there is clinically significant impairment in social, academic or occupational functioning and the symptoms cannot be better explained by another psychiatric disorder.
Although there is no ?cure? for ADHD, there are accepted treatments that specifically target its symptoms. The most common standard treatments include educational approaches, psychological or behavioral modification, and medication.
For further information please contact:
Porter Novelli for Shire
Jennifer Anello
212.601.8132
203.470.0836 (on site at meeting)
Alana Brier 212.601.8432
Poster #B60
October 25, 2007; 11:00 a.m. EST
Long-Term (Up To 12 Months) Use of the Methylphenidate Transdermal System
Frank A. López, M.D., Oscar G. Bukstein, M.D., Robert L. Findling, M.D., John M. Turnbow, M.D., Jonathan Rubin, M.D.
Children?s Developmental Center, Winter Park, FL; Western Psychiatric Institute and Clinic, Pittsburgh, PA; University Hospitals Case Medical Center, Cleveland, OH; Westex Clinical Investigations, Lubbock, TX; Shire Development Inc., Wayne, PA.
Important Safety Information
Tell your doctor about any heart conditions, including structural abnormalities, your child or a family member may have. Inform your doctor immediately if the child develops symptoms that suggest heart problems, such as chest pain or fainting.
Daytrana should not be used if the child has: significant anxiety, tension, or agitation; allergies to methylphenidate or other ingredients of Daytrana; glaucoma; discontinued in the last 14 days or is taking a monoamine oxidase inhibitor (MAOI); tics, or family history or diagnosis of Tourette?s syndrome.
Tell your doctor before using Daytrana if the child: is being treated for or has symptoms of depression (e.g. sadness, worthlessness, or hopelessness) or bipolar disorder; has family history of tics; has abnormal thoughts or visions, hears abnormal sounds, or has been diagnosed with psychosis; has had seizures or abnormal EEGs; has or has had high blood pressure; exhibits aggressive behavior or hostility. Tell your doctor immediately if the child develops any of these conditions/symptoms while using Daytrana.
In clinical studies, side effects were generally mild to moderate. The most common side effects reported with Daytrana were decreased appetite, sleeplessness, sadness/crying, twitching, weight loss, nausea, vomiting, tics, and affect lability (mood swings). Aggression, new abnormal thoughts/behaviors, mania, and growth suppression have been associated with use of drugs of this type. Tell your doctor if the child has blurred vision while using Daytrana.
Abuse of Daytrana can lead to dependence.
Daytrana should be applied daily to clean, dry skin, which is free of any cuts or irritation. Skin redness or itching is common with Daytrana. Allergic skin rash may occur.
For Full Prescribing Information go to www.DAYTRANA.com.
Notes to editors:
SHIRE PLC
Shire?s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire?s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company?s Web site: www.shire.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:
Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire?s results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development (including the successful development of JUVISTA® (Human TGFb3)), manufacturing and commercialization (including the launch and establishment in the market of VYVANSE); the impact of competitive products, including, but not limited to the impact of those on Shire?s Attention Deficit and Hyperactivity Disorder (?ADHD?) franchise; patents, including but not limited to, legal challenges relating to Shire?s ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of INTUNIV? (guanfacine) extended release (ADHD) and GA-GCB (Gene-Activated Glucocerebrosidane); Shire?s ability to secure new products for commercialization and/or development; Shire?s ability to benefit from its acquisition of New River Pharmaceuticals Inc.; and other risks and uncertainties detailed from time to time in Shire plc?s filings with the Securities and Exchange Commission, particularly Shire plc?s Annual Report on Form 10-K for the year endedDecember 31, 2006.
Daytrana? is a trademark of Shire Pharmaceuticals Ireland Limited.
###
Attention Deficit Disorder Without Hyperactivity: A Growing Problem Among Children
Although attention deficit hyperactivity disorder is the most commonly talked about disorder in children today, attention deficit disorder without hyperactivity is just as much of a problem. ADHD is more easily diagnosed because the hyperactivity is easy to see. So it is important for parents to know what to look for to determine whether their child has Attention deficit disorder without hyperactivity.
An Overview Of Homeopathy Adhd Treatments
Through a number of trials Homeopathy ADHD treatments have shown to be effective in reducing the ADHD symptoms of restlessness, inattentiveness and impulsiveness.
Attention Deficit Disorder
Attention Deficit Disorder and Attention Deficit Hyperactivity Disorder (ADD/ADHD) have been widely used labels since the early 1990s. They are considered catch-all diagnoses by many clinicians.
What is Hyperactivity in Attention Deficit Hyperactivity Disorder?
Most of the ADHD kids that are seen in a private practice setting are hyperactive kids simply because they get into the most trouble. Their parents are usually pulling their hair out and saying, "We've got to get this child some help.
New Drug Approved to Treat ADHD
The new drug Vyvanse received approval on Monday by the Food and Drug Administration to affectively treat Attention Deficit Hyperactivity Disorder. Although the medication received approval, it will come with a black box warning due to the possible side affects of the amphetamine contained in the medication.
Common Add Adhd Checklist Signs
Does you child show signs of being impulsive, hyperactive and inattentive? Then he or she might be showing some symptoms of ADHD. If you are concerned about your child?s behavior then checking the common signs and symptoms on an ADD/ADHD checklist can help to determine if further assessment is needed.
Tips for High School Teachers with ADHD Students: Setting Up Your Room
Thank you to all of our professional educators who dedicate themselves to our children! We know how difficult it can be working with ADHD children, so here are your teacher tips for the week, brought to you by the ADHD Information Library and ADDinSchool.com.
Appropriate ADHD Medication For Child - Meds For ADHD Child
Dealing and treating with children suffering from ADHD everyday, I engage a number of parents many of which are despondent about their childs condition, and more often than not, I end up offering consoling and emotional support to the parents than the children. They would often as on what is the best medication for an adhd child. It is a parents nightmare that their child should suffer and be in pain, but such parents forget one very crucial fact with ADHD: it is a readily treatable and curable condition.
Meeting The True Needs of Children Diagnosed As ADHD
How should one look upon Attention Deficit Hyperactivity Disorder (ADHD) and what is the effective way to aid those who are given this diagnosis? There has been considerable debate as to whether or not ADHD is a genuine disorder. Psychiatrist and professor Robert Hedaya (1996, pg.
School Issues: When Should an ADHD Child Be Held Back In School?
This can be a very complicated issue, so I don't mean to suggest that my comments here are the definitive thoughts on the subject. For a parent to even consider the issue, things have to be pretty problematic at school.
Ritalin (Methylphenidate) in the Treatment of Attention Deficit Hyperactivity Disorder
Ritalin is a good medication with a bad reputation. Its name causes more fear in the hearts of parents than any other medication.
ADHD: A Dialogue With a Non-Believer, part two
Dear Sir,
It was with some interest that I read the article What You Should Know About Attention Deficit Disorder by Edward W. after having it handed to me by a member of our church.
Symptoms And Treatments Of Attention Deficit Disorder (ADD)
Attention Deficit Disorder is a chronic neurological disorder, which is predominantly diagnosed in children. Statistics estimates that 2-5 % of the population is affected by ADD, considering the rare possibility for cases of Adult ADD. ADD is one of the disturbing pediatric disorders in the United States, since 5 million are affected by this disorder. Attention deficit disorder is the old name of the disease with characteristic symptoms of hyperactivity, inattention and impulsivity, which is later renamed as Attention Deficit Hyperactivity Disorder (AD HD). The disorder is classified into three distinct subtypes, ADHD predominantly combined type, ADHD predominantly inattentive type and ADHD predominantly hyperactive-impulsive type, on the b...
Callin All Parents Who Are Looking For Information On ADHD
It can be hard to find good information on ADHD. We have a society that is so quick to Medicate, after all, that often other solutions are ignored. Don't get me wrong, ADHD medication can be very helpful for a lot of people. Whether you suffer from adult ADHD, ADD, or childhood attention deficit disorder, there are many medical options to choose from. Nonetheless, there has been some evidence that taking Ritalin in the long term is not very good for the health. It is easy to pop a pill, of course, but it is not the only solution. There is information on ADHD that indicates that there are other, perhaps better choices.
Child ADHD - Deciding Where to Draw the Line
The wonderful adaptability of children in dealing with the challenges of this ever-changing and unpredictable world is really amazing. Their growth from a state of familial security and dependence through progressive stages of self-direction and personal autonomy requires enormous and almost anti-gravitational efforts on their part.